Elderly patients with hypertension,Gastrointestinal tumor screening
Conditions
Interventions
Group remimazolam:Sufentanil 0.1 µg/kg + remazolam [induction: 0.3 mg/kg, maintenance: 0.2-1 mg/kg/h]
Flumazenil 2 ml/0.2 mg [given after stopping the remazolam and repeated every 2 min until the patient awakens, with the maximum dose not exceeding 1 mg]
Group propofol:Sufentanil 0.1 µg/kg + propofol [induction 1.5 mg/kg, maintenance: 2-6 mg/kg/h (0-1 µg/kg/min)]
Saline 2 ml [given after cessation of propofol, repeated every 2 min until the patient awoke]
Sponsors
Sichuan Cancer Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Elderly hypertensive patients who were to undergo painless gastroenteroscopy; (2) Age 65-75 years; (3) Weight 50-70 kg; (4) ASA classification of II-III and cardiac function class I-II; (5) History of primary hypertension with blood pressure controlled within 160/90mmHg after standardized treatment.
Exclusion criteria
Exclusion criteria: (1) Patients who refused to participate in the trial; (2) Patients whose hypertension is not treated with regular medication; (3) Patients with a history of severe cardiac, cerebral, pulmonary, hepatic, renal and metabolic diseases; (4) Those with a previous history of recovery from abnormal surgical anesthesia; (5) Electrocardiogram suggestive of a heart rate <50 beats/min; (6) History of acute inflammation of the respiratory tract within 2 weeks with no cure; (7) Those with neuromuscular system diseases and psychiatric diseases; (8) Patients with anemia; (9) Persons with suspected abuse of narcotic analgesics or sedatives; (10) Persons who are predicted to have or have had a difficult airway; (11) Persons with known hypersensitivity to emulsions, benzodiazepines, and opioids; (12) Those who are uncooperative and unable to communicate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Hypotension;Cardiac function indices [cardiac index (CI), left ventricular output (CO), peripheral vascular resistance (SVR), pulse pressure variability (PPV), perfusion index (PI)] ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Respiratory Depression;Intraoperative adverse effects;Dosage of Sedative drug;Onset time of sedative drugs; Awakening time of patient; Satisfaction of patient and endoscopist;postoperative adverse effects; | — |
Countries
China
Contacts
Public ContactShu Jinjun
Sichuan Cancer Hospital
Outcome results
None listed